stockrow
Saturday 7 November 2026
Export LONA’s income statement to Excel — free account
LeonaBio, Inc.
LONA Healthcare Biotechnology
- EPS
- +55.6%
- Free cash flow
- −142.3%
Quarter to June 2026, against a year earlier
4.42
0.08
+1.84%
Follow LONA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 8 | 8 | 8 | 0.0% | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (5) | (5) | (20) | (55) | (96) | (118) | (97) | (106) | (141) | +54.2% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (5) | (5) | (20) | (55) | (96) | (118) | (97) | (106) | (141) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (14.69) | (14.47) | (16.70) | (14.90) | (25.30) | (30.90) | (25.20) | (24.70) | (23.11) | +7.7% | ||||||
| Cash flow | — | — | (12.92) | (10.41) | (20.15) | (11.67) | (19.21) | (26.50) | (25.25) | (10.69) | (2.61) | (2.7%) | ||||||
| Capex | — | — | 0.00 | 0.00 | (1.94) | (0.43) | (0.30) | (0.08) | (0.01) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (12.92) | (10.41) | (22.09) | (12.10) | (19.51) | (26.58) | (25.26) | (10.69) | (2.61) | (2.7%) | ||||||
| Book value | — | — | 6.24 | (7.49) | 229.20 | 86.97 | 62.32 | 34.24 | 11.65 | 6.50 | 1.42 | +0.6% | ||||||
| Shares, m | — | — | 0 | 0 | 1 | 4 | 4 | 4 | 4 | 4 | 13 | +43.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (4) | (4) | (24) | (43) | (72) | (101) | (97) | (46) | (62) | +39.3% | |||||
| Capex | — | — | — | — | (2) | (2) | (1) | 0 | 0 | — | 0 | (65.5%) | ||||||
| Free cash flow | — | — | (4) | (4) | (26) | (45) | (74) | (101) | (97) | (46) | (62) | +39.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 4 | 1 | 188 | 252 | 186 | 126 | 42 | 42 | 47 | +38.3% | |||||
| Net debt | — | — | (4) | (1) | (185) | (254) | (200) | (147) | (51) | (88) | (51) | +55.1% | ||||||
| Shareholders’ equity | — | — | 2 | (3) | 274 | 321 | 235 | 130 | 45 | 28 | 34 | +44.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (206.65) | (144.93) | (14.16) | (17.94) | (32.41) | (56.25) | (88.52) | (139.94) | (306.05) | +66.7 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | (13.95) | (59.43) | (186.85) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 29.45 | 29.82 | (15.68) | (18.43) | (34.39) | (64.42) | (110.77) | (290.81) | (431.39) | (320.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 22 | 35 | 64 | 67 | 26 | 19 | — | (2.9%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
LeonaBio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion, Inc. | $42.6M | — (loss-making) | — | — | n/m | +47.80% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ATHE Alterity Therapeutics Limited - Sponsored ADR | $42.4M | — (loss-making) | — | — | 0.00% | −84.83% (below 0%: shrinking) | 0.00% | — | Compare |
| GANX Gain Therapeutics, Inc. | $41.9M | — (loss-making) | — (loss-making) | +27.78% (above 0%: growing) | n/m | +8.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SER Serina Therapeutics, Inc. | $41.9M | — (loss-making) | — (loss-making) | +2,500.00% (above 0%: growing) | n/m | −76.82% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| SGMOQ Sangamo Therapeutics, Inc. | $41.9M | — (loss-making) | — (loss-making) | −77.60% (below 0%: shrinking) | n/m | +26.21% (above 0%: growing) | 100.00% | (2,215.40%) | Compare |
| LONA LeonaBio, Inc. | $40.9M | — (loss-making) | — | — | n/m | −142.29% (below 0%: shrinking) | 0.00% | 0.00% | |
| ATNM Actinium Pharmaceuticals, Inc. | $40.9M | 3.9× | 8.4× | +77,677.78% (above 0%: growing) | n/m | −4.91% (below 0%: shrinking) | 100.00% | 78.76% | Compare |
| HYPD Hyperion DeFi, Inc. | $39.8M | — (loss-making) | 0.5× | +2,333.33% (above 0%: growing) | n/m | +86.82% (above 0%: growing) | 100.00% | 8,668.63% | Compare |
| DWTX Dogwood Therapeutics, Inc | $39.8M | — (loss-making) | — | — | n/m | +10.31% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $41.9M | — | — | +2,333.33% | — | +9.27% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 11 May 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.42m | 1.95m | 31,000.00 |
| 2024 | 3.18m | 1.15m | 24,000.00 |
Ownership
Directors and executive officers, together
25.73%
Perceptive Entities
19.99%
Joseph Edelman
19.99%
Anders Hove
6.35%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement